SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-055442
Filing Date
2024-06-25
Accepted
2024-06-25 09:28:53
Documents
3
Period of Report
2024-06-25

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0208451-6k_nlspharm.htm 6-K 16743
2 NASDAQ PANEL GRANTS NLS PHARMACEUTICS' REQUEST FOR EXTENSION TO COMPLY WITH CONT ea020845101ex99-1_nlspharm.htm EX-99.1 10904
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5536
  Complete submission text file 0001213900-24-055442.txt   36458
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 241066347
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)